又2款创新器械获批：质子治疗系统与脑深部刺激系统

Core Insights - The National Medical Products Administration (NMPA) has approved two innovative medical devices for market launch: a proton therapy system from Varian Medical Systems and a deep brain stimulation system from Jingyu Medical Technology [2][3]. Proton Therapy System - The proton therapy system consists of an accelerator subsystem and a treatment subsystem, designed for treating solid malignant tumors and specific benign diseases. It features a cantilevered design that saves space and improves treatment efficiency [4][6]. - Varian Medical Systems Particle Therapy Company, a subsidiary of Varian Medical Systems, focuses on the research, production, and application of proton therapy technology. Varian was acquired by Siemens Healthineers for $16.4 billion in 2021, becoming a significant part of Siemens' business [6]. Deep Brain Stimulation System - The approved products from Jingyu Medical include an implanted deep brain stimulator, an electrode lead, and an extension lead, which together form a deep brain stimulation system aimed at treating opioid addiction [7][16]. - This system targets the nucleus accumbens and the anterior limb of the internal capsule, providing auxiliary treatment for patients with severe opioid addiction, thus filling a technological gap in physical interventions for opioid addiction treatment [16][18]. - Jingyu Medical Technology, established in 2011, specializes in deep brain stimulation systems and has received regulatory approvals for devices used in treating Parkinson's disease, obsessive-compulsive disorder, depression, and drug addiction [18].